Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 8:10 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 4,242 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder (MDD)
Interventions
MSI-195, Placebo
Drug
Lead sponsor
MSI Methylation Sciences, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Encino, California • Escondido, California + 30 more
Conditions
PTSD, Alcohol Use Disorders, Substance Use Disorders
Interventions
Risk Reduction through Family Therapy, Treatment as Usual
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
13 Years to 18 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Keratosis Pilaris
Interventions
Placebo, AO+Mist
Other
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Antidepressant Effects of Nitrous Oxide

NCT05357040
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Osteoarthritis Pain, Chronic Low Back Pain, Pain Due to Interstitial Cystitis
Interventions
placebo, tanezumab
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Overland Park, Kansas
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Conditions
Healthy Participants
Interventions
Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Terminated No phase listed Observational Accepts healthy volunteers

Imaging Biomarker for Addiction Treatment Outcome

NCT03427424
Conditions
Opioid-Related Disorders, Alcohol-Related Disorders
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Computer-Assisted Tailored Cue-card Health [CATCH] Study

NCT01170741
Conditions
Human Immunodeficiency Virus, STDs, Hepatitis, Viral, Human
Interventions
Tailored Cue Cards
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Depression, Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Interventions
Sertraline (Zoloft), Simvastatin (Zocor)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

The Trans-Led Care Study

NCT06880705
Conditions
Substance Abuse, Substance Addiction, Substance Use Disorder (SUD), Substance Use (Drugs, Alcohol), Human Immunodeficiency Virus (HIV)
Interventions
The TLC Program
Behavioral
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
COVID-19, SARS-CoV-2
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Conditions
Psoriasis, Arthritic
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
Conditions
Non Small Cell Lung Cancer
Interventions
NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 28 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Nasal Vestibulitis
Interventions
Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 16 more
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy Product-MCO-010, Sham Injection
Biological · Procedure
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Conditions
Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Galvokimig, Placebo
Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Newport Beach, California • Brandon, Florida • Plantation, Florida + 3 more
Conditions
Post-operative Pain, Post-partum Pain, Cesarean Section Complications
Interventions
Ketorolac
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
16 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Arthritis, Juvenile Idiopathic
Interventions
Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Conditions
Type1 Diabetes
Interventions
350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Drug
Lead sponsor
Immunomolecular Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chula Vista, California • Aurora, Colorado • Renton, Washington